###begin article-title 0
###xml 92 97 92 97 <sup xmlns:xlink="http://www.w3.org/1999/xlink">INK4a</sup>
The chromatin remodelling factor BRG1 is a novel binding partner of the tumor suppressor p16INK4a
###end article-title 0
###begin p 1
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
###end p 1
###begin title 2
Background
###end title 2
###begin p 3
###xml 0 10 0 10 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CDKN2A/p16</italic>
###xml 10 16 10 16 <italic xmlns:xlink="http://www.w3.org/1999/xlink">INK4a </italic>
###xml 10 16 10 16 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>INK4a </italic></sup>
###xml 136 142 136 142 <sup xmlns:xlink="http://www.w3.org/1999/xlink">INK4a </sup>
###xml 346 352 346 352 <sup xmlns:xlink="http://www.w3.org/1999/xlink">INK4a </sup>
###xml 509 515 509 515 <sup xmlns:xlink="http://www.w3.org/1999/xlink">INK4a </sup>
###xml 41 46 <span type="species:ncbi:9606">human</span>
###xml 472 477 <span type="species:ncbi:4932">yeast</span>
CDKN2A/p16INK4a is frequently altered in human cancers and it is the most important melanoma susceptibility gene identified to date. p16INK4a inhibits pRb phosphorylation and induces cell cycle arrest, which is considered its main tumour suppressor function. Nevertheless, additional activities may contribute to the tumour suppressor role of p16INK4a and could help explain its specific association with melanoma predisposition. To identify such functions we conducted a yeast-two-hybrid screen for novel p16INK4a binding partners.
###end p 3
###begin title 4
Results
###end title 4
###begin p 5
###xml 22 28 22 28 <sup xmlns:xlink="http://www.w3.org/1999/xlink">INK4a </sup>
###xml 126 132 126 132 <sup xmlns:xlink="http://www.w3.org/1999/xlink">INK4a </sup>
###xml 213 219 213 219 <sup xmlns:xlink="http://www.w3.org/1999/xlink">INK4a </sup>
###xml 301 306 301 306 <sup xmlns:xlink="http://www.w3.org/1999/xlink">INK4a</sup>
###xml 361 366 361 366 <sup xmlns:xlink="http://www.w3.org/1999/xlink">INK4a</sup>
###xml 545 551 545 551 <sup xmlns:xlink="http://www.w3.org/1999/xlink">INK4a </sup>
We now report that p16INK4a interacts with the chromatin remodelling factor BRG1. We investigated the cooperative roles of p16INK4a and BRG1 using a panel of cell lines and a melanoma cell model with inducible p16INK4a expression and BRG1 silencing. We found evidence that BRG1 is not required for p16INK4a-induced cell cycle inhibition and propose that the p16INK4a-BRG1 complex regulates BRG1 chromatin remodelling activity. Importantly, we found frequent loss of BRG1 expression in primary and metastatic melanomas, implicating this novel p16INK4a binding partner as an important tumour suppressor in melanoma.
###end p 5
###begin title 6
Conclusion
###end title 6
###begin p 7
###xml 144 150 144 150 <sup xmlns:xlink="http://www.w3.org/1999/xlink">INK4a </sup>
This data adds to the increasing evidence implicating the SWI/SNF chromatin remodelling complex in tumour development and the association of p16INK4a with chromatin remodelling highlights potentially new functions that may be important in melanoma predisposition and chemoresistance.
###end p 7
###begin title 8
Background
###end title 8
###begin p 9
###xml 41 47 41 47 <sup xmlns:xlink="http://www.w3.org/1999/xlink">INK4a </sup>
###xml 237 238 237 238 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 270 276 270 276 <sup xmlns:xlink="http://www.w3.org/1999/xlink">INK4a </sup>
###xml 446 451 446 451 <sup xmlns:xlink="http://www.w3.org/1999/xlink">INK4a</sup>
###xml 631 637 631 637 <sup xmlns:xlink="http://www.w3.org/1999/xlink">INK4a </sup>
###xml 721 727 721 727 <sup xmlns:xlink="http://www.w3.org/1999/xlink">INK4a </sup>
###xml 804 805 804 805 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 851 857 851 857 <sup xmlns:xlink="http://www.w3.org/1999/xlink">INK4a </sup>
###xml 76 81 <span type="species:ncbi:9606">human</span>
The cyclin dependent kinase inhibitor p16INK4a is frequently inactivated in human cancers and is a highly penetrant melanoma susceptibility gene; more than 50 germline mutations have been identified in high-risk melanoma-prone families [1]. The principal function of p16INK4a is to inhibit cell cycle progression by preventing the cyclin dependent kinases CDK4 and CDK6 from phosphorylating the retinoblastoma protein, pRb. In the presence of p16INK4a, pRb remains hypophosphorylated and forms active pRb-E2F transcriptional repressor complexes that silence genes required for S-phase entry. Consequently, ectopic expression of p16INK4a promotes pRb-dependent G1 cell cycle arrest and senescence. Moreover, functional p16INK4a is commonly maintained in pRb-deficient tumors (reviewed by Sherr & Roberts [2]), and this underscores the dependency of p16INK4a on the pRb pathway.
###end p 9
###begin p 10
###xml 173 174 173 174 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 175 176 175 176 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 401 402 401 402 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 494 495 494 495 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 554 558 554 558 <sup xmlns:xlink="http://www.w3.org/1999/xlink">Waf1</sup>
###xml 563 569 563 569 <sup xmlns:xlink="http://www.w3.org/1999/xlink">INK4b </sup>
###xml 576 582 576 582 <sup xmlns:xlink="http://www.w3.org/1999/xlink">INK4a </sup>
###xml 583 584 583 584 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 585 586 585 586 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 751 753 751 753 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 821 823 821 823 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 944 945 944 945 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 946 948 946 948 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 1045 1047 1045 1047 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 1134 1136 1134 1136 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 1137 1139 1137 1139 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 719 723 <span type="species:ncbi:10090">mice</span>
###xml 860 865 <span type="species:ncbi:9606">human</span>
Hypophosphorylated pRb can repress gene transcription at least partly by remodelling chromatin structure through its interactions with proteins such as HDAC1, BRM and BRG1 [3-5]. As the catalytic core of the SWI/SNF chromatin remodelling complex, the interaction between BRG1 and pRb was proposed to recruit the complex to E2F responsive promoters and enhance pRb transcriptional repressor activity. [5] There is also evidence that BRG1 acts upstream of pRb by repressing cyclin D1 expression [6] and upregulating the expression of the CDK inhibitors p21Waf1, p15INK4b and p16INK4a [7-9] to maintain pRb in an active, hypophosphorylated state. Not surprisingly, BRG1 may function as a tumor suppressor; BRG1 hemizygous mice are susceptible to tumors [10], while complete loss of BRG1 potentiates lung cancer development [11] and BRG1 is silenced or mutated in human tumor cell lines derived from breast, ovarian, lung, brain and colon cancers [4,12]. BRG1 is also lost in established neuroendocrine carcinomas and adenocarcinomas of the cervix [13], and the loss of BRG1 expression in lung cancer is associated with a poor prognosis [14,15].
###end p 10
###begin p 11
###xml 93 99 93 99 <sup xmlns:xlink="http://www.w3.org/1999/xlink">INK4a </sup>
###xml 99 106 99 106 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo</italic>
###xml 197 203 197 203 <sup xmlns:xlink="http://www.w3.org/1999/xlink">INK4a </sup>
###xml 254 260 254 260 <sup xmlns:xlink="http://www.w3.org/1999/xlink">INK4a </sup>
###xml 367 373 367 373 <sup xmlns:xlink="http://www.w3.org/1999/xlink">INK4a </sup>
###xml 388 394 388 394 <sup xmlns:xlink="http://www.w3.org/1999/xlink">INK4a </sup>
###xml 588 593 588 593 <sup xmlns:xlink="http://www.w3.org/1999/xlink">INK4a</sup>
###xml 621 623 621 623 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 709 714 709 714 <sup xmlns:xlink="http://www.w3.org/1999/xlink">INK4a</sup>
###xml 876 882 876 882 <sup xmlns:xlink="http://www.w3.org/1999/xlink">INK4a </sup>
###xml 154 159 <span type="species:ncbi:9606">human</span>
In this study, it is identified for the first time that BRG1 specifically associates with p16INK4a in vivo, and that both proteins are frequently lost in human melanomas. Although both BRG1 and p16INK4a regulate pRb activity we found no evidence that p16INK4a and BRG1 co-operate in cell cycle regulation. Targeted silencing of BRG1 did not diminish pRb-dependent p16INK4a activities; p16INK4a retained potent cell cycle inhibitory activity and induced senescence in the presence and absence of BRG1. Contrary to previous reports, that BRG1-deficient cells are relatively resistant to p16INK4a-induced cell cycle arrest [16], we show that pRb activity is BRG1-independent and thus, BRG1 does not influence p16INK4a-mediated cell cycle inhibition. Together with the frequent loss in primary melanomas the novel BRG1 interaction with the melanoma associated tumor suppressor p16INK4a implies an important role for BRG1 in melanoma.
###end p 11
###begin title 12
Results
###end title 12
###begin title 13
###xml 14 19 14 19 <sup xmlns:xlink="http://www.w3.org/1999/xlink">INK4a</sup>
BRG1 binds p16INK4a
###end title 13
###begin p 14
###xml 58 64 58 64 <sup xmlns:xlink="http://www.w3.org/1999/xlink">INK4a </sup>
###xml 196 198 196 198 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1A</xref>
###xml 355 357 355 357 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 407 413 407 413 <sup xmlns:xlink="http://www.w3.org/1999/xlink">INK4a </sup>
###xml 518 524 518 524 <sup xmlns:xlink="http://www.w3.org/1999/xlink">INK4a </sup>
###xml 644 646 644 646 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1B</xref>
###xml 814 816 814 816 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1C</xref>
###xml 7 12 <span type="species:ncbi:4932">yeast</span>
###xml 49 54 <span type="species:ncbi:9606">human</span>
###xml 416 421 <span type="species:ncbi:9606">human</span>
From a yeast two-hybrid screen using full-length human p16INK4a as bait, we isolated the C-terminal 530 amino acids of the chromatin remodelling factor BRG1 as a potential binding partner (Figure 1A). This segment of BRG1 incorporates the ATPase domain, which facilitates ATP hydrolysis, and the bromodomain, which enables binding to acetylated histones [17]. To confirm that full-length BRG1 also binds p16INK4a in human cells, both proteins were co-expressed transiently in U2OS osteosarcoma cells and MYC-tagged p16INK4a was specifically co-purified with FLAG-tagged BRG1 in immunoprecipitation assays using a FLAG-specific antibody (Figure 1B). Further, when both proteins were co-expressed in the SW-13 adrenocortical carcinoma cell line, they co-localized in the nucleus in distinct nuclear speckles (Figure 1C).
###end p 14
###begin p 15
###xml 29 35 29 35 <sup xmlns:xlink="http://www.w3.org/1999/xlink">INK4a </sup>
###xml 0 50 0 50 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Identification of BRG1 as p16<sup>INK4a </sup>binding partner</bold>
###xml 52 54 52 54 <bold xmlns:xlink="http://www.w3.org/1999/xlink">A </bold>
###xml 160 162 160 162 <bold xmlns:xlink="http://www.w3.org/1999/xlink">B </bold>
###xml 202 208 202 208 <sup xmlns:xlink="http://www.w3.org/1999/xlink">INK4a </sup>
###xml 361 367 361 367 <sup xmlns:xlink="http://www.w3.org/1999/xlink">INK4a </sup>
###xml 436 438 436 438 <bold xmlns:xlink="http://www.w3.org/1999/xlink">C </bold>
###xml 573 579 573 579 <sup xmlns:xlink="http://www.w3.org/1999/xlink">INK4a </sup>
###xml 126 131 <span type="species:ncbi:4932">yeast</span>
###xml 287 292 <span type="species:ncbi:10090">mouse</span>
###xml 325 330 <span type="species:ncbi:10090">mouse</span>
Identification of BRG1 as p16INK4a binding partner. A Schematic illustration of BRG1 highlighting the domains isolated in the yeast 2-hybrid screen (Y2H clone) B U2OS cells were transfected with MYC-p16INK4a and FLAG-BRG1 or control vector and immunoprecipitations were performed with a mouse-anti-FLAG antibody or a matched mouse IgG as indicated. BRG1 and p16INK4a were detected on immunoblots with anti-FLAG and anti-MYC antibodies. C Fluorescent microscopy images (FM) and confocal microscopy images (CF) of SW-13 cells grown on cover slips and transfected with MYC-p16INK4a and FLAG-BRG1 and probed with anti-FLAG and anti-MYC antibodies.
###end p 15
###begin p 16
###xml 54 59 54 59 <sup xmlns:xlink="http://www.w3.org/1999/xlink">INK4a</sup>
###xml 98 104 98 104 <sup xmlns:xlink="http://www.w3.org/1999/xlink">INK4a </sup>
###xml 171 173 171 173 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 179 185 179 185 <sup xmlns:xlink="http://www.w3.org/1999/xlink">INK4a </sup>
###xml 350 352 350 352 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2A</xref>
###xml 366 371 366 371 <sup xmlns:xlink="http://www.w3.org/1999/xlink">INK4a</sup>
###xml 431 437 431 437 <sup xmlns:xlink="http://www.w3.org/1999/xlink">INK4a </sup>
###xml 453 455 453 455 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2B</xref>
###xml 507 513 507 513 <sup xmlns:xlink="http://www.w3.org/1999/xlink">INK4a </sup>
###xml 598 603 598 603 <sup xmlns:xlink="http://www.w3.org/1999/xlink">INK4a</sup>
###xml 630 632 630 632 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2C</xref>
###xml 303 308 <span type="species:ncbi:9606">human</span>
###xml 547 552 <span type="species:ncbi:9606">human</span>
To verify that endogenous BRG1 also interacts with p16INK4a, we initially utilized the WMM1175_p16INK4a inducible melanoma cell model, which we have previously described [18]. p16INK4a expression was induced with IPTG to reach physiologically relevant levels comparable to those seen in the WS-1 normal human dermal fibroblasts at passage 20 (Figure 2A). Using a p16INK4a-specific antibody we isolated BRG1 from nuclear WMM1175_p16INK4a lysates (Figure 2B). Importantly, the interaction between BRG1 and p16INK4a was also confirmed in WS-1 normal human dermal fibroblasts at passage 20, using a p16INK4a-specific antibody (Figure 2C).
###end p 16
###begin p 17
###xml 14 20 14 20 <sup xmlns:xlink="http://www.w3.org/1999/xlink">INK4a </sup>
###xml 0 60 0 60 <bold xmlns:xlink="http://www.w3.org/1999/xlink">BRG1 binds p16<sup>INK4a </sup>in melanoma cells and normal fibroblasts</bold>
###xml 62 64 62 64 <bold xmlns:xlink="http://www.w3.org/1999/xlink">A </bold>
###xml 147 153 146 152 <sup xmlns:xlink="http://www.w3.org/1999/xlink">INK4a </sup>
###xml 265 271 264 270 <sup xmlns:xlink="http://www.w3.org/1999/xlink">INK4a </sup>
###xml 300 302 296 298 <bold xmlns:xlink="http://www.w3.org/1999/xlink">B </bold>
###xml 313 319 309 315 <sup xmlns:xlink="http://www.w3.org/1999/xlink">INK4a </sup>
###xml 352 358 348 354 <sup xmlns:xlink="http://www.w3.org/1999/xlink">INK4a </sup>
###xml 461 467 457 463 <sup xmlns:xlink="http://www.w3.org/1999/xlink">INK4a </sup>
###xml 598 604 594 600 <sup xmlns:xlink="http://www.w3.org/1999/xlink">INK4a </sup>
###xml 647 652 643 648 <sup xmlns:xlink="http://www.w3.org/1999/xlink">INK4a</sup>
###xml 668 670 664 666 <bold xmlns:xlink="http://www.w3.org/1999/xlink">C </bold>
###xml 720 726 716 722 <sup xmlns:xlink="http://www.w3.org/1999/xlink">INK4a </sup>
###xml 447 452 <span type="species:ncbi:10090">mouse</span>
###xml 489 494 <span type="species:ncbi:10090">mouse</span>
###xml 612 617 <span type="species:ncbi:10090">mouse</span>
###xml 632 638 <span type="species:ncbi:9986">rabbit</span>
###xml 750 755 <span type="species:ncbi:9606">human</span>
BRG1 binds p16INK4a in melanoma cells and normal fibroblasts. A 50 mug of total cell lysates derived from uninduced (-) and induced (+) WMM1175_p16INK4a cells and WS-1 fibroblasts (passage 20) were separated using a 15% SDS-PAGE gel. Immunoblots were probed for p16INK4a and beta-actin as indicated. B WMM1175_p16INK4a cells were induced to express p16INK4a with 4 mM IPTG or mock treated for 72 hours. Immunoprecipitations were performed using a mouse anti-p16INK4a antibody or a matched mouse IgG from nuclear cell lysate, as indicated. Immunoblots were probed for endogenous BRG1 and induced p16INK4a using a mouse anti-BRG1 and rabbit anti-p16INK4a, respectively. C Endogenous BRG1 was co-immunoprecipitated with p16INK4a from WS-1 normal dermal human fibroblasts grown to passage 20 as detailed above.
###end p 17
###begin title 18
###xml 15 20 <span type="species:ncbi:9606">human</span>
pRb pathway in human cell lines
###end title 18
###begin p 19
###xml 36 42 36 42 <sup xmlns:xlink="http://www.w3.org/1999/xlink">INK4a </sup>
###xml 106 111 106 111 <sup xmlns:xlink="http://www.w3.org/1999/xlink">INK4a</sup>
###xml 134 136 134 136 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 137 139 137 139 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 161 162 161 162 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3</xref>
###xml 173 174 173 174 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 179 185 179 185 <sup xmlns:xlink="http://www.w3.org/1999/xlink">INK4a </sup>
###xml 376 381 376 381 <sup xmlns:xlink="http://www.w3.org/1999/xlink">INK4a</sup>
###xml 449 455 449 455 <sup xmlns:xlink="http://www.w3.org/1999/xlink">INK4a </sup>
###xml 487 493 487 493 <sup xmlns:xlink="http://www.w3.org/1999/xlink">INK4a </sup>
###xml 968 978 968 978 <sup xmlns:xlink="http://www.w3.org/1999/xlink">Leu1163Pro</sup>
###xml 981 983 981 983 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
To establish the role of BRG1 on p16INK4a function we selected six cancer cell lines, varying in their p16INK4a, pRb and BRG1 status [12,16]. As shown in Figure 3 and Table 1, p16INK4a expression was inversely related to pRb expression and only detected in the pRb-negative SAOS-2 osteosarcoma and C33A cervical cancer cells. All other cell lines had detectable pRb and no p16INK4a. (Note, there is a slight leakage of the ectopically introduced p16INK4a in the p16-inducible WMM1175_p16INK4a cells without IPTG upon long exposure.) The BRG1 homologue, BRM was expressed in all but the C33A cells and SW-13 adrenocortical carcinoma cells. Importantly, SW-13 and C33A cells were also negative or extremely low for BRG1 expression levels. The H1299 lung cancer cells were deficient for BRG1 expression, and all remaining cell lines had detectable levels of BRG1. It is also worth noting that the HCT116 cells carry only a mutated, functionally impaired BRG1 allele (BRG1Leu1163Pro) [12]. CDK4 was expressed strongly in all cell lines, while its homologue, CDK6 was either absent or poorly expressed in the pRb negative SAOS-2 and C33A cells and present in the remaining cells.
###end p 19
###begin p 20
###xml 0 34 0 34 <bold xmlns:xlink="http://www.w3.org/1999/xlink">pRb pathway proteins in cell lines</bold>
pRb pathway proteins in cell lines. Expression of BRG1 and BRM was analyzed using 50 mug of nuclear cell lysates. All other proteins were analyzed from 50 mug of total cell lysates.
###end p 20
###begin p 21
pRb pathway proteins in cell lines
###end p 21
###begin p 22
###xml 122 124 122 124 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
Expression of the indicated proteins is summarized with + or -. Mutant status of BRG1 in HCT-116 cells has been reported [12].
###end p 22
###begin title 23
###xml 3 9 3 9 <sup xmlns:xlink="http://www.w3.org/1999/xlink">INK4a </sup>
p16INK4a requires pRB to induce cell cycle arrest
###end title 23
###begin p 24
###xml 35 41 35 41 <sup xmlns:xlink="http://www.w3.org/1999/xlink">INK4a </sup>
###xml 91 97 91 97 <sup xmlns:xlink="http://www.w3.org/1999/xlink">INK4a </sup>
###xml 282 288 282 288 <sup xmlns:xlink="http://www.w3.org/1999/xlink">INK4a </sup>
###xml 301 307 301 307 <sup xmlns:xlink="http://www.w3.org/1999/xlink">INK4a </sup>
###xml 437 443 437 443 <sup xmlns:xlink="http://www.w3.org/1999/xlink">INK4a </sup>
###xml 630 632 630 632 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 703 709 703 709 <sup xmlns:xlink="http://www.w3.org/1999/xlink">INK4a </sup>
###xml 850 856 850 856 <sup xmlns:xlink="http://www.w3.org/1999/xlink">INK4a </sup>
###xml 982 983 982 983 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4</xref>
###xml 1013 1018 1013 1018 <sup xmlns:xlink="http://www.w3.org/1999/xlink">INK4a</sup>
To define the impact of BRG1 on p16INK4a function we transiently expressed either BRG1, p16INK4a or both proteins in this panel of six cell lines. The short-term expression of BRG1 alone had no effect on the cell cycle distribution of the cell lines tested. As expected, neither p16INK4a alone nor p16INK4a in combination with BRG1 promoted cell cycle arrest in cells deficient for pRb (SAOS-2 and C33A). In contrast, introduction of p16INK4a induced potent cell cycle arrest in all cell lines expressing pRb (U2OS, H1299, HCT116, SW-13) even when the cells lacked BRG1 (H1299) or carried a reported mutant form of BRG1 (HCT116) [12]. Further, co-expression of BRG1 did not significantly enhance the p16INK4a induced cell cycle arrest in the U20S, H1299 or HCT116 cells. Importantly even in SW13 cells, which lack both BRG1 and its homologue BRM, p16INK4a expression alone induced a significant cell cycle arrest and this was enhanced to some extent by over-expressing BRG1 (Figure 4). These data confirm that p16INK4a-induced cell cycle arrest requires intact pRb, but not BRG1.
###end p 24
###begin p 25
###xml 12 18 12 18 <sup xmlns:xlink="http://www.w3.org/1999/xlink">INK4a </sup>
###xml 0 42 0 42 <bold xmlns:xlink="http://www.w3.org/1999/xlink">BRG1 and p16<sup>INK4a </sup>in cell cycle regulation</bold>
###xml 94 99 94 99 <sup xmlns:xlink="http://www.w3.org/1999/xlink">INK4a</sup>
BRG1 and p16INK4a in cell cycle regulation. Indicated cell lines were transfected with MYC-p16INK4a, FLAG-BRG1 and/or a control vector plus GFP-spectrin. Cells were fixed with 70% ethanol 48 hours post transfection and cellular DNA was stained with propidium iodide. Percent S-phase change of GFP-spectrin positive cells was calculated (percent S-phase vector control - percent S-phase sample) x 100/percent S-phase vector control.
###end p 25
###begin title 26
###xml 3 9 3 9 <sup xmlns:xlink="http://www.w3.org/1999/xlink">INK4a </sup>
p16INK4a does not require BRG1 to promote cell cycle arrest or induce cell senescence
###end title 26
###begin p 27
###xml 61 67 61 67 <sup xmlns:xlink="http://www.w3.org/1999/xlink">INK4a </sup>
###xml 129 135 129 135 <sup xmlns:xlink="http://www.w3.org/1999/xlink">INK4a </sup>
###xml 348 353 348 353 <sup xmlns:xlink="http://www.w3.org/1999/xlink">INK4a</sup>
###xml 448 453 448 453 <sup xmlns:xlink="http://www.w3.org/1999/xlink">INK4a</sup>
###xml 572 578 572 578 <sup xmlns:xlink="http://www.w3.org/1999/xlink">INK4a </sup>
###xml 597 602 597 602 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5A, B</xref>
To thoroughly evaluate any functional interaction between p16INK4a and BRG1, we stably silenced BRG1 in the inducible WMM1175_p16INK4a cell model. These cells were transfected with a silencing molecule specifically targeting BRG1 or a non-specific (NS) silencing molecule directed to the luciferase transcript. Two BRG1-silenced clones, WMM1175_p16INK4a_siBRG1 W9 and X1, with > 95% reduction in BRG1 accumulation and two control clones WMM1175_p16INK4a_sicontrol E1 and X2, with unaltered BRG1 expression, were selected for analysis. All clones remained inducible for p16INK4a expression (Figure 5A, B).
###end p 27
###begin p 28
###xml 23 29 23 29 <sup xmlns:xlink="http://www.w3.org/1999/xlink">INK4a </sup>
###xml 0 50 0 50 <bold xmlns:xlink="http://www.w3.org/1999/xlink">BRG1 does not alter p16<sup>INK4a </sup>cell cycle regulation</bold>
###xml 52 54 52 54 <bold xmlns:xlink="http://www.w3.org/1999/xlink">A </bold>
###xml 96 102 95 101 <sup xmlns:xlink="http://www.w3.org/1999/xlink">INK4a </sup>
###xml 264 266 263 265 <bold xmlns:xlink="http://www.w3.org/1999/xlink">B </bold>
###xml 321 327 319 325 <sup xmlns:xlink="http://www.w3.org/1999/xlink">INK4a </sup>
###xml 498 504 496 502 <sup xmlns:xlink="http://www.w3.org/1999/xlink">INK4a </sup>
###xml 520 522 515 517 <bold xmlns:xlink="http://www.w3.org/1999/xlink">C </bold>
###xml 570 572 565 567 <bold xmlns:xlink="http://www.w3.org/1999/xlink">D </bold>
###xml 824 826 819 821 <bold xmlns:xlink="http://www.w3.org/1999/xlink">E </bold>
###xml 872 874 867 869 <sup xmlns:xlink="http://www.w3.org/1999/xlink">3 </sup>
###xml 901 907 896 902 <sup xmlns:xlink="http://www.w3.org/1999/xlink">INK4a </sup>
BRG1 does not alter p16INK4a cell cycle regulation. A 50 mug of nuclear lysates from WMM1175_p16INK4a clones with stably integrated siRNA targeting BRG1 or a non-specific (NS) control siRNA were probed for BRG1 and topoisomerase II (Topo II) as a loading control. B 50 mug of total cell lysates extracted from WMM1175_p16INK4a cells stably expressing either a BRG1-specific siRNA or a non-specific (NS) siRNA molecule, as indicated, were treated with PBS (-) or IPTG (+) for 24 h and probed for p16INK4a and beta-actin. C Cell proliferation was determined by MTS assay. D A proportion of the IPTG/mock treated cells were analyzed for changes in cell cycle distribution. Percent S-phase change was calculated (percent S-phase mock treated cells - percent S-phase IPTG treated cells) x 100/percent S-phase mock treated cells. E The same clones were seeded at low density (103 cells/7.5 cm plate) and p16INK4a expression was induced with 4 mM IPTG or cells mock treated and colony forming ability was assayed after 14 days.
###end p 28
###begin p 29
###xml 115 121 115 121 <sup xmlns:xlink="http://www.w3.org/1999/xlink">INK4a </sup>
###xml 159 165 159 165 <sup xmlns:xlink="http://www.w3.org/1999/xlink">INK4a </sup>
###xml 244 246 244 246 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5C</xref>
###xml 365 367 365 367 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5D</xref>
###xml 509 515 509 515 <sup xmlns:xlink="http://www.w3.org/1999/xlink">INK4a </sup>
###xml 589 591 589 591 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5E</xref>
Silencing of BRG1 had no significant impact on the proliferation rate or cell cycle distribution of the WMM1175_p16INK4a cell line. In the absence of BRG1, p16INK4a retained the ability to inhibit the proliferation of the WMM1175 cells (Figure 5C), and this was associated with arrest in the G1-phase of the cell cycle with a concomitant S-phase inhibition (Figure 5D) that was maintained over the five-day induction period (data not shown). Moreover, the silencing of BRG1 had no impact on the ability of p16INK4a to totally prevent outgrowth of colonies upon low seeding density (Figure 5E).
###end p 29
###begin p 30
###xml 90 91 90 91 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 92 94 92 94 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 115 121 115 121 <sup xmlns:xlink="http://www.w3.org/1999/xlink">INK4a </sup>
###xml 219 221 219 221 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 264 269 264 269 <sup xmlns:xlink="http://www.w3.org/1999/xlink">INK4a</sup>
###xml 320 326 320 326 <sup xmlns:xlink="http://www.w3.org/1999/xlink">INK4a </sup>
###xml 340 346 340 346 <sup xmlns:xlink="http://www.w3.org/1999/xlink">INK4a </sup>
###xml 430 432 430 432 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F6">6A</xref>
###xml 516 518 516 518 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 519 521 519 521 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 532 534 532 534 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F6">6B</xref>
###xml 873 875 870 872 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 1044 1050 1038 1044 <sup xmlns:xlink="http://www.w3.org/1999/xlink">INK4a </sup>
###xml 1058 1060 1052 1054 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F6">6B</xref>
###xml 1068 1074 1062 1068 <sup xmlns:xlink="http://www.w3.org/1999/xlink">INK4a </sup>
###xml 1148 1150 1142 1144 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F6">6C</xref>
###xml 1301 1307 1295 1301 <sup xmlns:xlink="http://www.w3.org/1999/xlink">INK4a </sup>
BRG1 has been reported to induce senescence in SW-13 cells and in mesenchymal stem cells [7,19] and the role of p16INK4a in initiating and maintaining senescence is widely acknowledged (reviewed by Huschtscha & Reddel [20]). We investigated the role of BRG1 in p16INK4a-induced senescence. The long term induction of p16INK4a in WMM1175_p16INK4a cells was not influenced by the BRG1 status, caused pRb hypophosphorylation (Figure 6A) and induced senescence-like features in the WMM1175 cells as reported previously [18,21], (Figure 6B). These features included increased cell size and granularity, positive senescence-associated beta-galactosidase activity and the appearance of senescence-associated heterochromatin foci. Formation of foci coincides with the recruitment of pRb to E2F-responsive promoters and is associated with the stable repression of E2F-target genes [22]. This important marker of pRb activity was not affected by BRG1 silencing. Similarly, BRG1 silencing did not alter the build up of SA-beta-galactosidase induced by p16INK4a (Figure 6B) or p16INK4a induced changes in cell size and granularity in the WMM1175 cells (Figure 6C), the latter corresponds to senescence associated vacuolisation. This data confirms that cell cycle regulation and induction of cell senescence by p16INK4a does not require BRG1.
###end p 30
###begin p 31
###xml 23 29 23 29 <sup xmlns:xlink="http://www.w3.org/1999/xlink">INK4a </sup>
###xml 0 46 0 46 <bold xmlns:xlink="http://www.w3.org/1999/xlink">BRG1 does not alter p16<sup>INK4a </sup>driven senescence</bold>
###xml 59 65 59 65 <sup xmlns:xlink="http://www.w3.org/1999/xlink">INK4a </sup>
###xml 256 258 256 258 <bold xmlns:xlink="http://www.w3.org/1999/xlink">A </bold>
###xml 323 328 322 327 <sup xmlns:xlink="http://www.w3.org/1999/xlink">INK4a</sup>
###xml 349 356 348 355 <sup xmlns:xlink="http://www.w3.org/1999/xlink">807/811</sup>
###xml 395 397 391 393 <bold xmlns:xlink="http://www.w3.org/1999/xlink">B </bold>
###xml 420 425 416 421 <sup xmlns:xlink="http://www.w3.org/1999/xlink">INK4a</sup>
###xml 576 581 569 574 <sup xmlns:xlink="http://www.w3.org/1999/xlink">INK4a</sup>
###xml 819 821 810 812 <bold xmlns:xlink="http://www.w3.org/1999/xlink">C </bold>
###xml 989 995 980 986 <sup xmlns:xlink="http://www.w3.org/1999/xlink">INK4a </sup>
BRG1 does not alter p16INK4a driven senescence. WMM1175_p16INK4a cells, BRG1 silenced (clone X1, left panel) or NS (clone E1, right panel), were exposed to 4 mM IPTG over a five-day period and analyzed by FACS analysis, Western blot and imunocytostaining: A 50 mug of total cell lysate were immunoblotted and probed for p16INK4a, phospho-pRb (pRbSer807/811) and as a loading control beta-actin. B The accumulation of p16INK4a, the cell proliferation marker Ki67, chromatin condensation (DAPI) and the appearance of SA-beta-gal was analyzed by immunocytostaining in WMM1175_p16INK4a. Enlarged images of cells (indicated with arrows) show DAPI-stained chromatin foci. Histograms correspond to the average +/- s.d of at least two independent induction experiments from a total of at least 500 cells. LM, light microscopy. C FACS analysis by Forward Scatter (FSC) and Side Scatter (SSC) of clones demonstrate the senescence associated increase of cell size (FSC) and granularity (SSC) upon p16INK4a induction.
###end p 31
###begin title 32
BRG1 is lost in melanoma
###end title 32
###begin p 33
###xml 260 266 260 266 <sup xmlns:xlink="http://www.w3.org/1999/xlink">INK4a </sup>
###xml 274 275 274 275 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F7">7</xref>
###xml 300 301 300 301 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T2">2</xref>
###xml 460 466 460 466 <sup xmlns:xlink="http://www.w3.org/1999/xlink">INK4a </sup>
###xml 608 613 608 613 <sup xmlns:xlink="http://www.w3.org/1999/xlink">IN4a </sup>
###xml 689 694 689 694 <sup xmlns:xlink="http://www.w3.org/1999/xlink">INK4a</sup>
###xml 807 813 807 813 <sup xmlns:xlink="http://www.w3.org/1999/xlink">INK4a </sup>
###xml 900 906 900 906 <sup xmlns:xlink="http://www.w3.org/1999/xlink">INK4a </sup>
###xml 1156 1162 1156 1162 <sup xmlns:xlink="http://www.w3.org/1999/xlink">INK4a </sup>
###xml 1215 1220 <span type="species:ncbi:9606">human</span>
To evaluate the role of BRG1 in melanomas, we examined immunohistochemically stained paraffin sections from archival paraffin-embedded tissue blocks of a series of primary and metastatic melanomas for expression of the chromatin remodelling factor BRG1 and p16INK4a (Figure 7). As presented in Table 2, BRG1 expression was undetectable in 26/38 of melanomas (68%), whereas its homologue, BRM, was detected in 40/50 (80%) of melanoma specimens. As expected, p16INK4a was only detected in a small proportion 20% (9/45) of these primary and metastatic melanomas. Of 21 tumor samples with expression data for p16IN4a and BRG1 18 (86%) had lost at least one of these proteins, predominantly p16INK4a, and among these were 10 tumors (48%) negative for both, while 3 samples 14% had retained expression of both p16INK4a and BRG1. BRM and BRG1 showed consistent nuclear localisation in all samples, while p16INK4a was found to localise to the nucleus and cytoplasm. The proportion of BRG1 expression was slightly higher in the metastatic melanomas than in the primary melanomas, but, this did not reach significance using a Mann-Whitney Wilcoxon test. BRG1 and p16INK4a were readily detectable in cultured, normal, primary human melanocytes (data not shown) and therefore our data imply that BRG1-loss has an important role in melanoma development.
###end p 33
###begin p 34
###xml 46 52 46 52 <sup xmlns:xlink="http://www.w3.org/1999/xlink">INK4a </sup>
###xml 0 60 0 60 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Immunohistochemistry of melanomas for BRM, p16<sup>INK4a </sup>and BRG1</bold>
###xml 99 105 99 105 <sup xmlns:xlink="http://www.w3.org/1999/xlink">INK4a </sup>
Immunohistochemistry of melanomas for BRM, p16INK4a and BRG1. Melanoma samples were stained for p16INK4a and BRG1 with immunohistochemistry using DAB. BRM was stained using red fluorescence. Positive staining examples are presented in the right panel with no primary antibody control from the corresponding region in the left panel.
###end p 34
###begin p 35
BRG1 is frequently lost in melanomas
###end p 35
###begin p 36
###xml 41 47 41 47 <sup xmlns:xlink="http://www.w3.org/1999/xlink">INK4a </sup>
Immunohistological detection of BRG1, p16INK4a and BRM in primary and metastatic melanomas showing the proportion of samples with detectable positive staining.
###end p 36
###begin title 37
Discussion
###end title 37
###begin p 38
###xml 7 13 7 13 <sup xmlns:xlink="http://www.w3.org/1999/xlink">INK4a </sup>
###xml 176 181 176 181 <sup xmlns:xlink="http://www.w3.org/1999/xlink">INK4a</sup>
###xml 210 217 210 217 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo</italic>
The p16INK4a tumor suppressor has a critical influence on melanoma tumorigenesis. We have now shown that the chromatin remodelling factor BRG1 is a novel binding partner of p16INK4aand confirm this interaction in vivo. More importantly, we show that loss of BRG1 occurs frequently in primary and metastatic melanomas and propose that BRG1 may play an important role as a tumor suppressor in this cancer.
###end p 38
###begin p 39
###xml 27 33 27 33 <sup xmlns:xlink="http://www.w3.org/1999/xlink">INK4a </sup>
###xml 459 465 459 465 <sup xmlns:xlink="http://www.w3.org/1999/xlink">INK4a </sup>
###xml 488 489 488 489 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 490 492 490 492 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 547 549 547 549 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 657 658 657 658 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 808 809 808 809 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 1164 1170 1164 1170 <sup xmlns:xlink="http://www.w3.org/1999/xlink">INK4a </sup>
###xml 1379 1385 1379 1385 <sup xmlns:xlink="http://www.w3.org/1999/xlink">INK4a </sup>
###xml 1460 1466 1460 1466 <sup xmlns:xlink="http://www.w3.org/1999/xlink">INK4a </sup>
###xml 626 632 <span type="species:ncbi:10090">murine</span>
We have also shown that p16INK4a requires pRb, but not BRG1 to promote cell cycle arrest. This differs from several previous findings in the literature but agrees with others: It has been suggested that the pRb-BRG1 interaction is required for the pRb repression of E2F-target genes such as cyclin E and cyclin A, and thereby cell cycle arrest. According to this hypothesis, cells lacking BRG1 would harbor only inactive pRb, thus conferring resistance to p16INK4a induced growth arrest [5,16]. These findings differ from those of Bultman et al. [23] who did not observe a functional interaction between pRB and BRG1 in their murine models and Kang et al. [7], who showed that the BRG1-pRB interaction was not required for BRG1 induced cell cycle arrest in SW-13 cells. In contrast to our work, Kang et al. [7] used long-term BRG1 expression, which caused growth arrest in SW-13 cells, and showed that BRG1 bound the p21Waf1 promoter and upregulated its expression 3-7 days after BRG1 expression. This was sufficient to induce cell cycle arrest and senescence independent of the BRG1 ability to complex with pRb. In this study we have clearly demonstrated that p16INK4a requires pRb, but not BRG1, to promote cell cycle arrest. Our data is mainly based on the thorough analysis of a well-defined melanoma cell model, with inducible physiological relevant expression levels of p16INK4a and the use of highly specific BRG1-silencing molecules. In this model, p16INK4a induction promotes rapid G1-cell cycle arrest followed by cellular senescence, and these functions were not affected by silencing of BRG1.
###end p 39
###begin p 40
###xml 84 88 84 88 <sup xmlns:xlink="http://www.w3.org/1999/xlink">INK4</sup>
###xml 115 117 115 117 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 269 271 269 271 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 515 517 515 517 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B26">26</xref>
###xml 551 557 551 557 <sup xmlns:xlink="http://www.w3.org/1999/xlink">INK4a </sup>
###xml 659 664 659 664 <sup xmlns:xlink="http://www.w3.org/1999/xlink">INK4a</sup>
Chromatin changes, which involve chromatin remodelling, are an important step in p16INK4/pRb dependent senescence [24]. It was recently shown that the BRG1 homologue, BRM, forms an initiating component of heterochromatin complexes during the senescence of melanocytes [25]. BRG1 has also been implicated in senescence of melanocytes, as it has been identified in the SWI/SNF complex facilitating transcription in response to IGFBP7, the latter itself being an important player in oncogenic BRAF-induced senescence [26]. However, our data show that p16INK4a is able to promote senescence in WMM1175 melanoma cells in the absence of BRG1 indicating that the p16INK4a/pRb senescence pathway does not require BRG1.
###end p 40
###begin p 41
###xml 442 444 442 444 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
###xml 445 447 445 447 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
###xml 577 578 577 578 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 718 720 718 720 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
###xml 817 819 817 819 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B30">30</xref>
###xml 856 862 856 862 <sup xmlns:xlink="http://www.w3.org/1999/xlink">INK4a </sup>
###xml 863 865 863 865 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B31">31</xref>
###xml 895 901 895 901 <sup xmlns:xlink="http://www.w3.org/1999/xlink">INK4a </sup>
###xml 1017 1023 1017 1023 <sup xmlns:xlink="http://www.w3.org/1999/xlink">INK4a </sup>
###xml 1164 1169 1164 1169 <sup xmlns:xlink="http://www.w3.org/1999/xlink">INK4a</sup>
###xml 1219 1225 1219 1225 <sup xmlns:xlink="http://www.w3.org/1999/xlink">INK4a </sup>
As the catalytic component of the SWI/SNF chromatin remodelling complex, BRG1 facilitates unwinding of DNA helices bound to and wrapped around histone structures. The SWI/SNF chromatin remodelling complex can be recruited by specific DNA binding molecules such as transcriptional activators or repressors and directed to specific DNA targets. For instance, BRG1 promotes p53 dependent transcription by interacting with this tumor suppressor [27,28], while it functions as a co-repressor of E2F dependent transcription by associating with the E2F transcriptional repressor pRb [5]. Furthermore, BRG1 has recently been reported to promote transcriptional activity of the melanocyte specific transcription factor MITF-M [29]. MITF-M plays an important role in melanocyte proliferation and survival (reviewed by Goding) [30] and activates the expression of p16INK4a [31]. It is possible that the p16INK4a interaction with BRG1 modulates any one or more of these functions. For example it is tempting to speculate that p16INK4a influences MITF-M transcriptional activity via its association with BRG1. This would create an important feedback loop between MITF-M and p16INK4a. We are currently investigating the impact of p16INK4a on these BRG1 specific chromatin remodelling functions.
###end p 41
###begin p 42
###xml 42 48 42 48 <sup xmlns:xlink="http://www.w3.org/1999/xlink">INK4a </sup>
###xml 400 406 400 406 <sup xmlns:xlink="http://www.w3.org/1999/xlink">INK4a </sup>
###xml 407 409 407 409 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B32">32</xref>
###xml 707 713 707 713 <sup xmlns:xlink="http://www.w3.org/1999/xlink">INK4a </sup>
###xml 810 815 810 815 <sup xmlns:xlink="http://www.w3.org/1999/xlink">INK4a</sup>
###xml 1008 1010 1008 1010 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
###xml 1137 1139 1137 1139 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B33">33</xref>
###xml 1045 1054 <span type="species:ncbi:7955">zebrafish</span>
###xml 1197 1202 <span type="species:ncbi:9606">human</span>
Regardless of the function of the BRG1-p16INK4a complex, it is evident that BRG1 expression can be lost relatively early in melanoma development, with a significant proportion (> 70%) of primary melanomas showing no detectable BRG1 expression, while BRM expression was usually maintained in these tumors (< 20% loss). Overall, the rate of BRG1 loss was high in melanomas and comparable to that of p16INK4a [32], which suggests that selection against BRG1 expression arises relatively early in melanoma genesis. The fact that, additionally to the frequent loss of either tumor suppressor, a high proportion of melanomas show loss of both proteins correlates with our data showing BRG1-independence of the p16INK4a cell cycle regulatory functions and this suggests BRG1 independent and dependent functions of p16INK4a. BRG1 is proposed to be an important modulator of chromatin in melanocytic cells. In particular, BRG1 promotes transcriptional activity of the melanocyte specific transcription factor MITF-M [29], reduction of BRG1 expression in zebrafish embryos leads to a reduction in neural crest derived cells including melanocytes [33] and thirdly we found BRG1 expression in normal, primary human melanocytes. Therefore we propose that BRG1 is a vital melanoma associated tumour suppressor, which is frequently lost in the initial stages of the disease.
###end p 42
###begin p 43
###xml 246 248 246 248 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B34">34</xref>
###xml 382 384 382 384 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 385 387 385 387 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 489 491 489 491 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 602 604 602 604 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B35">35</xref>
###xml 673 675 673 675 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
###xml 746 748 746 748 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 902 904 902 904 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 1003 1005 1003 1005 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B36">36</xref>
###xml 1118 1120 1118 1120 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B37">37</xref>
###xml 712 716 <span type="species:ncbi:10090">mice</span>
The identification of BRG1 as a potential tumor suppressor in melanoma adds to the increasing evidence implicating the SWI/SNF chromatin remodelling complex in tumor development. BRG1 mutations have been identified in small cell lung carcinomas [34] and loss of BRG1 expression or mislocalisation of BRG1 to the cytoplasm has been associated with poor prognosis in this malignancy [14,15]. Another study showed that 71% of neuroendocrine carcinomas of the cervix had lost BRG1 expression [13] and BRG1 has been implicated in breast cancer through its role in estrogen receptor dependent transcription [35], its interaction with the breast cancer susceptibility gene BRCA1 [27] and because BRG1 haploinsufficient mice are prone to mammary tumors [23]. Furthermore, BRG1 is often lost or mutated in various tumor cell lines including cells derived from pancreatic, ovarian, lung, brain and colon cancer [12]. In primary melanoma, the chromosomal region of BRG1 (19p13.2) is not deleted at high frequency [36], nevertheless, translocations in this chromosomal region have been associated with the disease in three cases [37].
###end p 43
###begin title 44
Conclusion
###end title 44
###begin p 45
###xml 78 84 78 84 <sup xmlns:xlink="http://www.w3.org/1999/xlink">INK4a </sup>
We have identified BRG1 as a novel binding partner of the tumor suppressor p16INK4a and confirmed this interaction in normal cells. Together with our immunohistologic data confirming frequent BRG1 loss in primary melanomas, this implicates BRG1 as an important tumor suppressor in melanoma.
###end p 45
###begin title 46
Methods
###end title 46
###begin title 47
###xml 0 5 <span type="species:ncbi:4932">Yeast</span>
Yeast two-hybrid screen
###end title 47
###begin p 48
###xml 106 112 106 112 <sup xmlns:xlink="http://www.w3.org/1999/xlink">INK4a </sup>
###xml 162 168 162 168 <sup xmlns:xlink="http://www.w3.org/1999/xlink">INK4a </sup>
###xml 21 26 <span type="species:ncbi:4932">yeast</span>
###xml 141 146 <span type="species:ncbi:4932">yeast</span>
###xml 238 243 <span type="species:ncbi:9606">human</span>
The Matchmaker2 Gal4 yeast two-hybrid system (Clontech, Mountain View, CA, USA) was used to screen for p16INK4a binding partners in the Y190 yeast strain with p16INK4a cloned into the pAS2 vector in frame to the Gal4 binding domain and a human brain cDNA library cloned into the pACT2 vector in frame with the Gal4 transactivation domain (Clontech, Mountain View, CA, USA) according to the manufacturers instructions.
###end p 48
###begin title 49
Cell culture
###end title 49
###begin p 50
###xml 192 197 <span type="species:ncbi:9606">human</span>
###xml 287 293 <span type="species:ncbi:9913">bovine</span>
U2OS, SAOS-2 (osteosarcoma), HCT116 (colon cancer), NCI-H1299 (lung cancer, are referred to as H1299 throughout this manuscript), C33A (cervical cancer), SW-13 (adrenocarcinoma), WS-1 (normal human fibroblasts) and WMM1175_wtp16 (melanoma) cells were grown in DMEM media with 10% foetal bovine serum and in case of WMM1175_wtp16 cells this was supplemented with 250 mug/ml Hygromycin and 500 mug/ml geneticin (Invitrogen, Carlsbad, CA, USA). Transfections were performed with FuGene (Roche, Mannheim, Germany).
###end p 50
###begin title 51
###xml 24 30 24 30 <sup xmlns:xlink="http://www.w3.org/1999/xlink">INK4a </sup>
Stable BRG1 silenced p16INK4a inducible WMM1175 clones
###end title 51
###begin p 52
###xml 6 8 6 8 <sup xmlns:xlink="http://www.w3.org/1999/xlink">5 </sup>
###xml 516 522 514 520 <sup xmlns:xlink="http://www.w3.org/1999/xlink">INK4a </sup>
5 x 105 WMM1175_wtp16 cells were transfected with 4 mug of a BRG1 targeting siRNA (5'gatccGCATGCACCAGATGCACAAgttcaagagaCTTGTGCATCTGGTGCATGttttttggaaa3') cloned into the pSilencerPuro vector (Ambion, Austin, Texas, USA) or a control siRNA, targeting the luciferase gene, in the same vector supplied by Ambion. After selection with puromycin (2 mug/ml media) clones appeared after 20 days and were expanded, maintained with DMEM media including hygromycin, geneticin and puromycin and tested for BRG1 silencing and p16INK4a inducibility.
###end p 52
###begin title 53
Antibodies
###end title 53
###begin p 54
###xml 140 146 137 143 <sup xmlns:xlink="http://www.w3.org/1999/xlink">INK4a </sup>
###xml 243 249 240 246 <sup xmlns:xlink="http://www.w3.org/1999/xlink">INK4a </sup>
###xml 692 694 689 691 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B38">38</xref>
###xml 0 5 <span type="species:ncbi:10090">Mouse</span>
###xml 67 72 <span type="species:ncbi:10090">mouse</span>
###xml 125 131 <span type="species:ncbi:9986">rabbit</span>
###xml 229 234 <span type="species:ncbi:10090">mouse</span>
###xml 333 338 <span type="species:ncbi:10090">mouse</span>
###xml 405 411 <span type="species:ncbi:9986">rabbit</span>
###xml 494 500 <span type="species:ncbi:9986">rabbit</span>
###xml 588 592 <span type="species:ncbi:9925">goat</span>
###xml 652 658 <span type="species:ncbi:9986">rabbit</span>
###xml 698 703 <span type="species:ncbi:10090">mouse</span>
###xml 759 764 <span type="species:ncbi:10090">mouse</span>
###xml 820 826 <span type="species:ncbi:9986">rabbit</span>
###xml 899 904 <span type="species:ncbi:10090">mouse</span>
###xml 964 969 <span type="species:ncbi:10090">mouse</span>
Mouse anti-beta-actin (AC-74, Sigma, Castle Hill, NSW, Australia), mouse anti-Flag (M2, Sigma, Castle Hill, NSW, Australia), rabbit anti p16INK4a antibody (Western and immunohistochemistry, N-20, SantaCruz, Santa Cruz, CA, USA), mouse anti-p16INK4a antibody (immunoprecipitation, 2B4D11, Zymed Laboratories, San Francisco, CA, USA), mouse anti-BRG1 antibody (Western, G7, SantaCruz, Santa Cruz, CA, USA), rabbit anti-BRG1 antibody (immunohistochemistry, H-88, Santa Cruz, Santa Cruz, CA, USA), rabbit anti-MYC (A14, SantaCruz, Santa Cruz, CA, USA), Ki67 (MIB-1, Dako, Glostrup, Denmark), goat anti-BRM (Western, N-19, Santa Cruz, Santa Cruz, CA, USA), rabbit anti-BRM (immunohistochemistry, [38]), mouse anti-CDK4 (C8218, Sigma, Castle Hill, NSW, Australia), mouse anti-CDK6 (MS-451-P0, Neomarker, Union City, CA, USA), rabbit anti-phosphorylated pRb (Ser807/811, Cell Signalling, Boston, MA, USA), mouse anti-pRb (G3-245, BD Pharmingen, Franklin Lakes, NJ, USA), mouse anti-topoisomerase II (Ab1, Oncogene, San Diego, CA, USA),
###end p 54
###begin title 55
Immunoprecipitation
###end title 55
###begin p 56
###xml 40 41 40 41 <sup xmlns:xlink="http://www.w3.org/1999/xlink">6</sup>
###xml 130 132 128 130 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B39">39</xref>
###xml 773 779 770 776 <sup xmlns:xlink="http://www.w3.org/1999/xlink">INK4a </sup>
###xml 833 839 830 836 <sup xmlns:xlink="http://www.w3.org/1999/xlink">INK4a </sup>
###xml 458 463 <span type="species:ncbi:10090">mouse</span>
###xml 496 501 <span type="species:ncbi:10090">mouse</span>
###xml 788 793 <span type="species:ncbi:10090">mouse</span>
###xml 818 824 <span type="species:ncbi:9986">rabbit</span>
24 hours post seeding U2OS cells (2 x 106), they were transfected with 7 mug pCMV-Myc5b-p16 and either 10.5 mug pcDNA3-BRG1-Flag [39] or 10.5 mug pCMV-Flag5b vector (Promega, Madison, Wisconsin, USA). Cells were harvested 24 hours post transfection, lysed in IP-buffer (50 mM Tris pH7.4, 150 mM NaCl, 1 mM EDTA, 1% NP-40, 0.25% sodium deoxycholate, protease inhibitors (Complete tablets, Roche, Mannheim, Germany)) and immunoprecipitation was performed with mouse-anti-Flag antibody or a matched mouse IgG coupled to tosyl-activated Dynal beads (Dynal Biotech, Oslo, Norway) following the manufacturers instructions. Proteins were separated on a 5-15% gradient SDS-PAGE gel, transferred to PVDF membranes (Millipore, Billerica, MA, USA) and probed for FLAG-BRG1 and MYC-p16INK4a with the mouse-anti-FLAG antibody or a rabbit anti-p16INK4a antibody.
###end p 56
###begin p 57
###xml 91 97 91 97 <sup xmlns:xlink="http://www.w3.org/1999/xlink">INK4a </sup>
###xml 455 461 455 461 <sup xmlns:xlink="http://www.w3.org/1999/xlink">INK4a </sup>
###xml 172 177 <span type="species:ncbi:9606">human</span>
###xml 441 446 <span type="species:ncbi:10090">mouse</span>
###xml 483 488 <span type="species:ncbi:10090">mouse</span>
###xml 679 684 <span type="species:ncbi:10090">mouse</span>
For immunoprecipitations of endogenous BRG1 WMM1175_wtp16 cells were induced to express p16INK4a with 4 mM IPTG or mock treated for 72 hours; alternatively passage 20 WS-1 human dermal fibroblasts were used. Nuclear pellets were produced using low salt buffer (10 mM HEPES pH 7.9, 10 mM KCl, 0.1 mM EDTA, 0.1 mM EGTA, 1 mM DTT) and lyzed in IP-buffer with protease inhibitors. 5 mg of nuclear lysate was used for immunoprecipitation using a mouse anti-p16INK4a antibody or a matched mouse IgG. Protein antibody complexes were purified using protein-A-agarose (Santa Cruz, Santa Cruz, CA, USA). Immunoblotting was performed as described above, endogenous BRG1 was detected with a mouse anti-BRG1 antibody.
###end p 57
###begin title 58
Immunocytostaining
###end title 58
###begin p 59
###xml 29 31 29 31 <sup xmlns:xlink="http://www.w3.org/1999/xlink">5 </sup>
###xml 258 263 <span type="species:ncbi:10090">mouse</span>
###xml 278 284 <span type="species:ncbi:9986">rabbit</span>
###xml 338 342 <span type="species:ncbi:9925">goat</span>
###xml 348 353 <span type="species:ncbi:10090">mouse</span>
###xml 377 381 <span type="species:ncbi:9925">goat</span>
###xml 392 398 <span type="species:ncbi:9986">rabbit</span>
SW-13 cells were seeded at 105 cells on cover slips into 6-well plates and transfected 24 hours post seeding with 1 mug pCMV-MYC5b-p16 and 1.5 mug pcDNA3-BRG1-FLAG. Cells were fixed with methanol:acetone (1:1) for one minute, washed with PBS and probed with mouse anti-FLAG and rabbit anti-MYC antibodies and secondary Alexa Fluor 594 nm goat-anti-mouse and Alexa Fluor 488 nm goat anti-anti-rabbit antibodies (Invitrogen, Carlsbad, CA, USA). Images were taken with a BX-51 microscope and a SPOT camera and a FV1000 confocal microscope (Olympus, Center Valley, PA, USA).
###end p 59
###begin p 60
###xml 11 17 11 17 <sup xmlns:xlink="http://www.w3.org/1999/xlink">INK4a </sup>
###xml 149 151 149 151 <sup xmlns:xlink="http://www.w3.org/1999/xlink">4 </sup>
###xml 246 247 246 247 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 250 251 250 251 <sub xmlns:xlink="http://www.w3.org/1999/xlink">4</sub>
###xml 262 263 262 263 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 265 266 265 266 <sub xmlns:xlink="http://www.w3.org/1999/xlink">4</sub>
###xml 350 356 347 353 <sup xmlns:xlink="http://www.w3.org/1999/xlink">INK4a </sup>
WMM1175_p16INK4a cells silenced for BRG1 or expressing a control silencing molecule were seeded after 1, 3, 5 days induction with 4 mM IPTG at 4 x 104 cells on cover slips and fixed 8 hours later with 2% formaldehyde, 0.2% glutaraldehyde, 7 mM Na2HPO4, 1.5 mM KH2PO4, 140 mM NaCl, and 2.6 mM KCl and stained for SA-beta-galactosidase, DAPI, Ki67, p16INK4a and BRG1. Images were taken with a BX-51 microscope and a SPOT camera (Olympus, Center Valley, PA, USA).
###end p 60
###begin title 61
Western blotting
###end title 61
###begin p 62
###xml 202 207 198 203 <sup xmlns:xlink="http://www.w3.org/1999/xlink">INK4a</sup>
###xml 256 261 252 257 <sup xmlns:xlink="http://www.w3.org/1999/xlink">INK4a</sup>
50 mug total cell lysate or nuclear lysate was separated on 15% SDS-PAGE gels or 5-15% gradient SDS-page gels, transferred to PVDF membranes (Millipore, Billerica, MA, USA) and probed for beta-actin p16INK4a, BRG1, BRM, pRb, CDK6, phoshorylated pRb and p16INK4a.
###end p 62
###begin title 63
Cell proliferation assay
###end title 63
###begin p 64
###xml 11 17 11 17 <sup xmlns:xlink="http://www.w3.org/1999/xlink">INK4a </sup>
###xml 101 103 101 103 <sup xmlns:xlink="http://www.w3.org/1999/xlink">3 </sup>
###xml 339 341 339 341 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2 </sup>
WMM1175_p16INK4a cells silenced for BRG1 or expressing a control silencing molecule were seeded at 103 cells per well in 96 well plates. For each day one plate was assayed for MTS levels using a CellTitre 96 Aqueous One Solution Proliferation assay (Promega, Madison, Wisconsin, USA) according to the manufacturer's protocol using a Victor2 1420 Multilable counter (Perkin Elmer).
###end p 64
###begin title 65
Cell cycle distribution
###end title 65
###begin p 66
###xml 2 4 2 4 <sup xmlns:xlink="http://www.w3.org/1999/xlink">5 </sup>
105 cells were seeded per well into 6-well plates and 24 hours later transfected with 1 mug pCMV-MYC5b-p16 and/or 1.5 mug pcDNA3-BRG1-FLAG or 2.5 mug pCMV-MYC5b vector plus 250 ng pEGFPspectrin. Total transfected DNA was adjusted to 2.75 mug with pCMV-MYC5b vector. Cells were harvested 48 hours post transfection and fixed in 4degreesC 70% ethanol for at least 1 hour and stained with 50 mug/ml propidium iodide and 50 mug/ml RNasesA in PBS and analyzed using a FACScalibur and ModFit software (Becton Dickinson, Franklin Lakes, NJ, USA). Percent S-phase change was calculated (percent S-phase vector control - percent S-phase sample) x 100/percent S-phase vector control.
###end p 66
###begin p 67
WMM1175_wtp16 cells expressing a siRNA targeting BRG1 or a control siRNA molecule targeting luciferase were induced for 1, 3 or 5 days with 4 mM IPTG or mock treated. For each time point the cell cycle distribution was determined as described above.
###end p 67
###begin title 68
Immunohistochemistry
###end title 68
###begin p 69
###xml 617 623 605 611 <sup xmlns:xlink="http://www.w3.org/1999/xlink">INK4a </sup>
###xml 421 425 <span type="species:ncbi:9925">goat</span>
###xml 687 691 <span type="species:ncbi:9925">goat</span>
###xml 697 703 <span type="species:ncbi:9986">rabbit</span>
###xml 1197 1201 <span type="species:ncbi:9925">goat</span>
###xml 1207 1213 <span type="species:ncbi:9986">rabbit</span>
###xml 1438 1443 <span type="species:ncbi:10090">mouse</span>
###xml 1462 1468 <span type="species:ncbi:9986">rabbit</span>
###xml 1491 1497 <span type="species:ncbi:9986">rabbit</span>
Paraffin-embedded formaldehyde fixed primary (Breslow depth of invasion > 2 mm) or metastatic melanomas were cut at 4 mm onto Superfrost Plus slides and dried at 60degreesC for 1 hour. Sections were rehydrated through histolene and ethanol, heated in antigen retrieval buffer (Dako, Glostrup, Denmark) overnight at 70degreesC. Slides were placed in 3% hydrogen peroxide for 10 min then blocked for 1 hour with 50% normal goat serum (Serum Australis, Tamworth, NSW, Australia) diluted in 1% Tween 20/tris buffered saline (TTBS). Samples were incubated with primary antibodies for 1 hour at dilutions indicated. For p16INK4a and BRG1 slides were incubated for 30 minutes with biotinylated goat anti-rabbit (Dako, Glostrup, Denmark) diluted 1:400 in TBT (1%BSA in TTBS) and finally for 30 minutes with biotinylated-HRP/streptavidin (Invitrogen, Carlsbad, CA, USA) diluted in TBT. Antibodies were detected using 3,3'-diaminobenzidine tetrachloride (DAB; Invitrogen, Carlsbad, CA, USA), counter stained with Mayers Haemotoxylin (Sigma, Castle Hill, NSW, Australia), dehydrated and mounted using Normount (Fronine, Riverstone, NSW, Australia). For BRM, slides were incubated for 1 hour with Alexa Fluor goat anti-rabbit 594 nm (Invitrogen, Carlsbad, CA, USA) diluted 1:1000 with DAPI (Sigma, Castle Hill, NSW, Australia) diluted 1:2000 in TBT. Slides were washed then mounted using 3% n-propylgallate/50% glycerol. Primary antibodies used were mouse anti-p16 (1:200), rabbit anti-BRG1 (1:100) and rabbit anti-BRM1 (1:400). Sections were scored for staining intensity as 0 (equal to control), 1 (very weak positive)), 2 (positive) and 3 (strong positive) and the proportion of tumor tissue with positive staining as 0 (none), 1 (< 10%), 2 (< 50%) and 3 (> 50%). Tumors were considered to have detectable positive staining when the (intensity score) x (proportion staining score) was > 1. Only tumor samples with enough tissue for staining of at least two of the proteins were included in the study. Appropriate negative and positive controls were used with each batch of immunostaining. This study is covered by the Sydney South West Area Health Service Ethics Review Committee (RPAH Zone) Protocol No. X08-0155 & HREC Ref. 08/RPAH/262 - "Histological and Immunohistological Analysis of Melanocytic Tumours".
###end p 69
###begin title 70
Competing interests
###end title 70
###begin p 71
The authors declare that they have no competing interests.
###end p 71
###begin title 72
Authors' contributions
###end title 72
###begin p 73
###xml 339 344 <span type="species:ncbi:9606">human</span>
TB conceived and designed the project, carried out the initial Y2H screen, participated in and supervised most experimental work and drafted the manuscript. SH participated with endogenous IPs and carried out most of the senescence work. MD isolated and identified BRG1 from Y2H candidate clones and confirmed BRG1-p16INK4a interaction in human cells. LS participated in the design of the study and carried out the immunohistochemistry. MF carried out confocal microscopy. ED contributed her expertise in Y2H work. RS was critically involved in the immunohistochemistry analysis. DN contributed resources and was involved in the design of the study. GM was involved in the design of the study and the analysis. RK was involved in the design of the study and the analysis. HR participated in the senescence work and was critically involved in design and coordination of the study and the analysis and helped to draft the manuscript. All authors revised the manuscript and approved the final version.
###end p 73
###begin title 74
Acknowledgements
###end title 74
###begin p 75
We thank Dr Mei Huang for providing the BRG1 expression plasmid. This study was supported by the University of Sydney Cancer Research Fund, the Cancer Council NSW, the Cancer Institute NSW and the National Health and Medical Research Council of Australia, NHMRC. HR is an NHMRC RD Wright Fellow, SH is supported by a scholarship from the German Academic Exchange Service, DAAD, and the Cancer Institute NSW, RS is a Cancer Institute NSW Clinical Research Fellow and LS is a Cameron Melanoma Research Fellow of the Melanoma and Skin Cancer Research Institute, University of Sydney.
###end p 75
###begin article-title 76
High-risk melanoma susceptibility genes and pancreatic cancer, neural system tumors, and uveal melanoma across GenoMEL
###end article-title 76
###begin article-title 77
CDK inhibitors: positive and negative regulators of G1-phase progression
###end article-title 77
###begin article-title 78
The COOH-terminal region of pRb2/p130 binds to histone deacetylase 1 (HDAC1), enhancing transcriptional repression of the E2F-dependent cyclin A promoter
###end article-title 78
###begin article-title 79
When the SWI/SNF complex remodels.the cell cycle
###end article-title 79
###begin article-title 80
Exit from G1 and S phase of the cell cycle is regulated by repressor complexes containing HDAC-Rb-hSWI/SNF and pRb-hSWI/SNF
###end article-title 80
###begin article-title 81
Inhibition of cyclin D1 gene by Brg-1
###end article-title 81
###begin article-title 82
BRG1 controls the activity of the retinoblastoma protein via regulation of p21CIP1/WAF1/SDI
###end article-title 82
###begin article-title 83
Role for BRG1 in cell cycle control and tumour suppression
###end article-title 83
###begin article-title 84
Re-expression of hSNF5/INI1/BAF47 in pediatric tumor cells leads to G1 arrest associated with induction of p16ink4a and activation of RB
###end article-title 84
###begin article-title 85
###xml 28 33 <span type="species:ncbi:10090">mouse</span>
A Brg1 null mutation in the mouse reveals functional differences among mammalian SWI/SNF complexes
###end article-title 85
###begin article-title 86
Targeted knockout of BRG1 potentiates lung cancer development
###end article-title 86
###begin article-title 87
BRG1, a component of the SWI-SNF complex, is mutated in multiple humantumour cell lines
###end article-title 87
###begin article-title 88
Downregulation of BRG-1 repressed expression of CD44s in cervical neuroendocrine carcinoma and adenocarcinoma
###end article-title 88
###begin article-title 89
Chromatin remodeling factors and BRM/BRG1 expression as prognostic indicators in non-small cell lung cancer
###end article-title 89
###begin article-title 90
###xml 20 25 <span type="species:ncbi:9606">human</span>
Loss of BRG1/BRM in human lung cancer cell lines and primary lung cancers: correlation with poor prognosis
###end article-title 90
###begin article-title 91
Restoration of retinoblastoma mediated signaling to Cdk2 results in cell cycle arrest
###end article-title 91
###begin article-title 92
###xml 76 81 <span type="species:ncbi:9606">human</span>
Structural ramification for acetyl-lysine recognition by the bromodomain of human BRG1 protein, a central ATPase of the SWI/SNF remodeling complex
###end article-title 92
###begin article-title 93
Functional impairment of melanoma-associated p16(INK4a) mutants in melanoma cells despite retention of cyclin-dependent kinase 4 binding
###end article-title 93
###begin article-title 94
###xml 96 99 <span type="species:ncbi:10116">rat</span>
Brg1 chromatin remodeling factor is involved in cell growth arrest, apoptosis and senescence of rat mesenchymal stem cells
###end article-title 94
###begin article-title 95
p16(INK4a) and the control of cellular proliferative life span
###end article-title 95
###begin article-title 96
p16INK4a-induced senescence is disabled by melanoma-associated mutations
###end article-title 96
###begin article-title 97
Rb-mediated heterochromatin formation and silencing of E2F target genes during cellular senescence
###end article-title 97
###begin article-title 98
###xml 58 62 <span type="species:ncbi:10090">mice</span>
Characterization of mammary tumors from Brg1 heterozygous mice
###end article-title 98
###begin article-title 99
Remodeling of chromatin structure in senescent cells and its potential impact on tumor suppression and aging
###end article-title 99
###begin article-title 100
###xml 106 111 <span type="species:ncbi:9606">human</span>
Dynamic assembly of chromatin complexes during cellular senescence: implications for the growth arrest of human melanocytic nevi
###end article-title 100
###begin article-title 101
Oncogenic BRAF induces senescence and apoptosis through pathways mediated by the secreted protein IGFBP7
###end article-title 101
###begin article-title 102
###xml 27 32 <span type="species:ncbi:9606">human</span>
BRCA1 is associated with a human SWI/SNF-related complex: linking chromatin remodeling to breast cancer
###end article-title 102
###begin article-title 103
The activity of p53 is differentially regulated by Brm- and Brg1-containing SWI/SNF chromatin remodeling complexes
###end article-title 103
###begin article-title 104
The microphthalmia-associated transcription factor requires SWI/SNF enzymes to activate melanocyte-specific genes
###end article-title 104
###begin article-title 105
Mitf from neural crest to melanoma: signal transduction and transcription in the melanocyte lineage
###end article-title 105
###begin article-title 106
MITF links differentiation with cell cycle arrest in melanocytes by transcriptional activation of INK4A
###end article-title 106
###begin article-title 107
Loss of expression of the p16/cyclin-dependent kinase inhibitor 2 tumor suppressor gene in melanocytic lesions correlates with invasive stage of tumor progression
###end article-title 107
###begin article-title 108
###xml 123 132 <span type="species:ncbi:7955">zebrafish</span>
Critical role of Brg1 member of the SWI/SNF chromatin remodeling complex during neurogenesis and neural crest induction in zebrafish
###end article-title 108
###begin article-title 109
Genetic and epigenetic screening for gene alterations of the chromatin-remodeling factor, SMARCA4/BRG1, in lung tumors
###end article-title 109
###begin article-title 110
BRG1/BRM and prohibitin are required for growth suppression by estrogen antagonists
###end article-title 110
###begin article-title 111
Distinct sets of genetic alterations in melanoma
###end article-title 111
###begin article-title 112
A t(1,19) chromosome translocation in three cases of malignant melanoma
###end article-title 112
###begin article-title 113
The reversible epigentic silencing of BRM: implications for clinical targeted therapy
###end article-title 113
###begin article-title 114
Chromatin-remodelling factor BRG1 selectively activates a subset of interferon-a-inducible genes
###end article-title 114

